MATERIAL AND METHODS

Gene expression data
We applied ProTINA to three datasets of drug treatments from NCI-DREAM drug synergy challenge (16) , genotoxicity study (17) and chromosome drug targeting study (18) , and to gene expression data of human lung cancer cell Calu-3 from influenza A viral infection studies (19) (20) (21) (22) . For NCI-DREAM drug synergy challenge, we obtained the raw Affymetrix Human Genome U219 microarray data from Gene Expression Omnibus (GEO) database (23) (accession number: GSE51068). The raw data were first normalized and transformed into log2-scaled expressions using justRMA function in the affy package of Bioconductor (24) . Then, the log 2 fold change (log2FC) differential expressions and their statistical significance (Benjamini-Hochberg adjusted p-values) were calculated using a linear fit model and empirical Bayes method in the limma package of Bionconductor. Three samples from the drug treatment using the low dose of Aclacinomycin A were dropped because all of the log2FC expressions were close to 1 and thus not statistically significant. The probe sets were mapped to gene symbols using hgu219.db annotation package (Entrez Gene database as of 27 th September 2015). In the case of multiple probe sets mapping to a gene symbol, we assigned the log2FC from the probe set with the smallest average adjusted p-value over the samples.
The raw microarray data from genotoxicity study (17) in human HepG2 cell line were obtained from GEO (accession numbers: GSE28878 using Affymetrix GeneChip Human Genome U133 Plus 2.0 array and GSE58235 using Affymetrix HT Human Genome U133+ PM array). As with the drug synergy data, the microarray data were first normalized using justRMA, and the log2FCs and their adjusted p-values were calculated using limma in Bioconductor. Because the data came from different microarray platforms, the gene symbols were matched separately for each platform using hgu133plus2.db annotation package (Entrez database of 27 th September 2015) and HT_HG-U133_Plus_PM annotation file in Affymetrix, respectively. Likewise, in the case of multiple probe sets matching a gene symbol, the probe set with the smallest average adjusted p-value across all samples was chosen.
The raw data from the chromosome-targeting study using mouse pancreatic alpha and beta cells (18) were also obtained from GEO database (ascension number: GSE36379). Again, the raw data were normalized using justRMA, and the log2FCs and their adjusted p-values were calculated by limma. The probes were mapped to the corresponding gene symbols using moe430a.db package (Entrez Gene database as of 27 th September 2015) in Bioconductor. In the case of multiple probe sets mapping to a gene symbol, we selected the probe set with the smallest average adjusted p-value among the samples.
For influenza A infection analysis, we obtained the raw microarray data of four influenza studies (19) (20) (21) (22) from GEO database (ascension numbers: GSE40844, GSE37571, GSE33142, andGSE28166). The raw data were background-corrected and normalized using normexp and quantile methods in limma package of Bioconductor. The log2FCs and their adjusted p-values were again calculated by limma. The probes were mapped to the corresponding gene symbols using hgug4112a.db package (Entrez Gene database as of 27th September 2015). Like before, for genes with multiple probe sets, we chose the logFC value corresponding to the probe set with the smallest average adjusted p-value.
Protein target identification using ProTINA
Protein-gene network. In ProTINA, the PGRN is a bipartite graph with weighted, directed edges pointing from a protein to a gene (see Fig. 1a ). For human PIN, we combined the protein-protein interactions from two databases, namely Enrichr (27) and STRING (28) . For mouse pancreatic cells, we obtained mouse (Mus musculus) PIN from the STRING database (28) . For each TF, we identified its protein partners, defined as proteins that are within a network distance of 2 from the TF in the PIN. When using the STRING database, we included all direct protein partners of TFs, and proteins with a network distance of 2 from TFs with a confidence score reported on STRING larger than 0.5. For human lymphoma, hepatocytes, and lung cancer cells, we identified 11,090 protein partners for a subset of 499 TFs (out of 515 TFs), 10,834 protein partners for a subset of 403 TFs (out of 413 TFs), and 6,175 protein partners for a subset of 504TFs (out of 515 TFs), respectively. For mouse pancreatic cells, we found 6,620 protein partners for a subset of 89 for example by including lesser confident TF-gene and protein-protein interactions or by including proteins with a network distance from TFs larger than 2, would allow the scoring of a higher number of proteins, such strategy often lowers the accuracy of the protein target predictions.
Gene transcription model. The edges in the PGRN have weights, whose magnitudes represent the strength of the gene regulation and whose signs indicate the direction or the mode of the regulation: positive for gene activation and negative for gene repression. The weights are inferred from the gene expression dataset by adapting a procedure described in our previous method DeltaNet (9, 29) . The inference of the edge weights is based on an ordinary differential equation (ODE) model of the mRNA production of a gene:
where r k (t) is the mRNA concentration of gene k at time t, u k and d k denotes the mRNA transcription and degradation rate constants respectively, and a kj denotes the gene regulatory influence (or edge weight) of the j-th protein on the k-th gene.
While the regulatory edges in the model above usually describe TF-gene interactions, in ProTINA, we further accounted for the (indirect) regulation of a gene by proteins that interact with the TFs. For this purpose, we considered a modified ODE model:
where a positive (negative) b kjq describes the activation (repression) of the k-th gene by a protein q through its interaction with the TF protein j. The variables n TF and n P denote the numbers of TFs and their protein partners, respectively. The multiplication of two variables r j and r q implies that the regulation of gene k by protein q requires the TF protein j (a non-zero r j ). The model in Equation (2) can be simplified into: 
where * kj a denotes the overall regulatory influence of each protein j, including TFs and their protein partners, on the expression of gene k. Note that the model in Equation (3) is mathematically equivalent to that in Equation (1).
By taking the pseudo-steady state assumption, the above model equation can be linearized using a logarithmic transformation (see derivation in ref. 9 ). The inference of the weights from the gene expression dataset involved the following linear regression problem: 
where c ki denotes the log2 fold-change (log2FC) expression for gene k in sample i. The variable p ki represents the part of log2FC of gene k expression in sample i that cannot be accounted for by the log2FC of its protein regulators. In other words, p ki indicates the perturbations to the expression of gene k. As detailed below, ProTINA relies on the magnitude and directions of such network perturbations (dysregulations) to identify proteins with altered gene regulatory activity.
The dynamical information contained in time-series gene expression profiles could greatly improve the inference of the edge weights above. As previously described in ref. 29 , such information could be accounted for by adding the following linear constraint on the linear regression problem: In ProTINA, the vectors A k and P k for each gene k in Equations (6) and (7) were estimated by ridge regression. The ridge regression provides a solution to an underdetermined linear regression problem of the standard form: y = Xβ + ε , using a penalized least square objective function:
λ is a shrinkage parameter for the L 2 -norm penalty. Equations (6) and (7) are rewritten into the
Before applying the ridge regression, we normalized the vectors of log2FCs and slopes to have a unit norm.
Self-loops were excluded in the regression, and thus the diagonal entries of A k were set to 0. In the applications of ProTINA, we employed 10-fold cross validations to determine the optimal λ , one that gives the minimum average prediction error. Here, we used the GLMNET package (31) for both the MATLAB and R versions of ProTINA.
Protein target scoring. In ProTINA, each candidate protein target is assigned a score based on the deviation of the expression of its downstream genes. More specifically, we computed the residuals of the linear regression problem in Equations (6) 
where r k is the 1× m vector of residuals for m samples. For each drug treatment, there often exist multiple gene expression profiles, taken at different time points or different doses. Correspondingly, we evaluated the z-score z lk for each drug treatment l and for each gene k, according to σ = lk lk k l r z n ( 9 ) where lk r denotes the average residual of gene k among the drug treatment samples, Consequently, a highly positive (negative) score s ji is an overall indicator of strongly enhanced (attenuated) regulatory activity of protein j by the drug treatment in sample i (see Fig. 1d ). The protein targets in each drug treatment sample are ranked in decreasing magnitude of the scores s ji .
DeMAND and differential expression analysis
For DeMAND analysis, we employed the public R subroutines available from the website:
http://califano.c2b2.columbia.edu/demand. Following the procedure detailed in the original publication (15) , we computed the RMA (Robust Multi-array Average) normalized gene expression values as inputs to the analysis. In DeMAND analysis, we used the same cell type-specific PGRNs as those in
ProTINA. For each candidate protein target, DeMAND evaluated the p-value of the deviations in the gene expression relationship between the protein target and each of the genes connected to this protein in the PGRN. The drug targets were ranked in increasing magnitude of the combined p-values.
In differential expression (DE) analysis, we calculated the log2FC differential expression of each protein in the PGRN, as described in section Gene expression data above. Here, we used the log2FC values directly as the target scores. Correspondingly, we ranked the candidate protein targets in decreasing magnitude of the log2FC gene expression values.
Performance assessment
For comparing the performance of different methods, we computed the area under the receiver operating characteristic curve (AUROC), i.e. the area under the plot of true positive rate against false positive rate, following the procedure adopted in DREAM challenges (33, 34) . For each method and each drug treatment, we generated a ranked list of protein targets according to decreasing magnitudes of the protein scores in ProTINA, increasing p-values of network dysregulation from DeMAND, and increasing magnitudes of log2FC gene expression from DE analysis.
Gene set enrichment analysis
For influenza A virus study, we performed a gene set enrichment analysis (GSEA) of the protein target predictions from ProTINA, DeMAND and DE analysis for the KEGG biological pathways (35),
using the R package GAGE (Generally Applicable Gene-set/pathway Enrichment analysis) with
Kolmogorov-Smirnov tests (36) . In the case of ProTINA and DeMAND, target proteins with zero score were excluded from the GSEA.
Reference protein targets
The reference protein targets of compounds in drug treatment studies were compiled from 5 different public databases of chemical-protein interactions: DrugBank (37), Therapeutic Target Database (TTD) (38) , MATADOR (39), Comparative Toxicogenomics Database (CTD) (40) , and STITCH (41) .
DrugBank and TTD provided information on the mechanism of drug actions as well as the proteins that have physical binding interactions with drugs. Meanwhile, MATADOR, CTD, and STITCH gave interactions between proteins and chemical compounds, curated from text mining and experimental evidences. When retrieving the protein targets of drugs from these databases, we collected proteins that directly bind to the queried drugs. The reference targets for each dataset in this study are provided in Supplementary material 1. Meanwhile, the reference protein targets for influenza A virus study were obtained from ref. 42 , where 1,292 host proteins that likely physically bind to viral proteins of influenza type A/WSN/33 in human embryonic kidney cells (HEK293) were identified by wholegenome co-immunoprecipitation assays.
RESULTS
New protein target prediction strategy
ProTINA takes advantage of the availability of comprehensive protein-protein and protein-DNA interaction databases to construct, when possible, a tissue or cell type-specific PGRN. The method considers a PGRN with weighted directed edges (see Fig. 1a ), describing direct and indirect gene transcriptional regulation by TFs and their protein partners. The edge weights are determined by applying ridge regression using the gene expression data based on a kinetic model of the gene transcriptional process (see Fig. 1b and Material and Methods). Here, a positive weight indicates a gene activation, while a negative weight implies a gene repression. Because of the underlying kinetic model, ProTINA is able to incorporate dynamical gene expression data, a common type of data from drug treatment studies (5, (16) (17) (18) . The scoring of drug targets is based on the enhancement or attenuation of protein-gene regulatory interactions caused by the drug treatment. A drug-induced gene regulatory enhancement occurs when the expression of genes that are positively (negatively) regulated by a candidate target, becomes higher (lower) in drug treated samples than what is predicted by the PGRN model (see Fig. 1c) . A drug-induced attenuation describes the opposite scenario, where the expression of positively (negatively) regulated genes of a target is lower (higher)
than expected from the model. For any given differential gene expression sample, a candidate protein target is scored based on the overall enhancement and/or attenuation of its regulatory influence on the downstream genes (see Fig. 1d and Material and Methods). Thus, a protein target with a more positive (negative) score is considered a more likely target of the drug, in which the drug treatment enhances (attenuates) the gene regulatory activity.
Prediction of known targets of drugs
We tested ProTINA's performance in predicting drug targets using gene expression data from three drug treatment studies employing human and mouse cell lines. The first dataset came from the NCI-DREAM drug synergy study using human diffuse large B cell lymphoma OCI-LY3 (16), the second from the compound genotoxicity study using human liver cancer cells HepG2 (17) , and the third from the chromatin-targeting compound study using mouse pancreatic cells (18) . We compared ProTINA to the state-of-the-art network-based analytical method DeMAND (15) , and to the traditional differential expression analysis (DE). For the analysis of datasets from human cell lines, we constructed cell-type specific PGRNs by combining human PIN from STRING (28) and Enrichr database (27) 
Mechanism of action of drugs
Besides high AUROCs, ProTINA also provided accurate and specific indications on the MoA of the compounds. In the NCI-DREAM synergy study, roughly half of the compounds are known to cause DNA damages, including DNA topoisomerase inhibitors (camptothecin, doxorubicin and etoposide), DNA crosslinker (mitomycin C), oxidative DNA damaging agent (methothrexate), and histone deacetylase (HDAC) inhibitors (trichostatin A). In demonstrating ProTINA's ability to reveal the compound MoA, we focused on the canonical p53 DNA damage response pathway (15) , as illustrated in Fig. 3 . Here, the activation of p53 in response to DNA damage is expected to induce the transcription of Cyclin Dependent Kinase Inhibitor 1A (CDKN1A) and Growth Arrest and DNA Damage Inducible Alpha (GADD45A) (43, 44) . In turn, CDKN1A and GADD45A -through their interactions with Proliferating Cell Nuclear Antigen (PCNA) -regulate the DNA replication and repair process (45) . GADD45A also inhibits the catalytic activity of Aurora Kinase A (AURKA) (46) , leading to a lowered activation of Polo-like Kinase 1 (PLK1) and Cyclin B1 (CCNB1) in a phosphorylation cascade (47, 48) . As shown in Fig. 4a , except for trichostatin A, the six proteins in the canonical p53 pathway above were ranked highly by ProTINA among the genotoxic compounds in the study (median rank <500), consistent with their known MoA. Note that the same six proteins were ranked much lower among the non-DNA damaging compounds (median rank >500), signifying a high specificity of ProTINA predictions (see also Supplementary Figure S1 ). Equally important, ProTINA was able to accurately identify the direction of the drug-induced alterations caused by the DNA damaging compounds. The signs of protein target scores from ProTINA indicated drug-induced enhancement (positive scores) of CDKN1A, PCNA, and GADD45A, and attenuation (negative scores) of CCNB1, AURKA, and PLK1 (see Supplementary Table S4 ), consistent with the expected response of these proteins to DNA damage in Fig. 3 .
As illustrated in Fig. 4a , DeMAND and DE analysis also performed reasonably well in predicting the compounds' MoA. But, the directions of the perturbations predicted by DE analysis were not always consistent with the expected response to DNA damage (see Supplementary Table S5-6) .
Meanwhile, DeMAND did not provide any information on the directions of the drug perturbations. In addition, the protein target scores of ProtTINA provided a clearer demarcation between the genotoxic and the non-genotoxic agents among the compounds in the dataset, than DeMAND and DE analysis (see Supplementary Figure S1 ). Besides the canonical p53 response pathway, we further looked at the ranking of proteins involved in the overall DNA damage repair (DDR) and its associated pathways (49) (see Supplementary material 2). As depicted in Fig. 4b , ProTINA ranked these proteins much higher than DeMAND and DE analysis, with DE performing the poorest among the methods considered.
In comparison to DeMAND and DE analysis, ProTINA was further able to detect a specific MoA of mitomycin C, whose DNA crosslinking activity is expected to prompt a particular DNA repair process called the fanconi anemia pathway (50) . The fanconi anemia pathway relies on a specific protein complex to ubiquitinate Fanconi Anemia Group D2 Protein (FANCD2) and Fanconi Anemia Group I Protein (FANCI), as well as two homologous recombination (HR) repair proteins, namely Breast Cancer Type 1 Susceptibility Protein (BRCA1) and RAD51 Recombinase (RAD51) (51) . In ProTINA analysis, the average rank of FANCD2, FANCI, BRCA1, and RAD51 was within top 100 for mitomycin C, while the average rank of those proteins was much greater than 100 for the other DNA damaging agents (see Supplementary Table S7 ). However, the specific activation of the fanconi anemia pathway by mitomycin C was not detected by DeMAND or DE analysis. Thus, ProTINA provided more sensitive and specific indications for the mechanism of action of compounds than DeMAND and DE.
Application of ProTINA for predicting pathogen-host interactions
We (19) (20) (21) (22) .
We employed ProTINA to compute the overall protein target scores using the gene expression data of Calu-3 from the four studies above, by averaging the scores from the early phase of the influenza infection between 0 to 12 hours. We checked the target predictions of ProTINA against the findings from a genome-wide co-immunoprecipitation analysis of host and viral protein interactions (42) . More specifically, the aforementioned study reported 1,292 host proteins that co-immunoprecipitated with viral proteins of influenza A/WSN/33 using human embryonic kidney cells (HEK293). Despite the discrepancy in the cell types and influenza viral strains between the co-immunoprecipitation analysis and the gene expression profiling, influenza A viruses share similar features and common protein interactions (52, 53) . Besides ProTINA, we also evaluated the accuracy of viral target predictions from DeMAND and DE for the same dataset. 
